# EDGAR Filing Document

**Accession Number:** 0001551306
**File Stem:** 0001551306-23-000026
**Filing Date:** 2023-3
**Character Count:** 4998
**Document Hash:** 00b6d4377545ed8d02b50e6e925d8630
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001551306-23-000026.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0001551306-23-000026

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230313

**ITEM INFORMATION**: Regulation FD Disclosure

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Progyny, Inc.
- **CENTRAL INDEX KEY:** 0001551306
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-MISC HEALTH & ALLIED SERVICES, NEC [8090]
- **IRS NUMBER:** 272220139
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39100
- **FILM NUMBER:** 23725858

**BUSINESS ADDRESS:**
- **STREET 1:** 1359 BROADWAY
- **STREET 2:** 2ND FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10018
- **BUSINESS PHONE:** 212-888-3124

**MAIL ADDRESS:**
- **STREET 1:** 1359 BROADWAY
- **STREET 2:** 2ND FLOOR
- **CITY:** NEW YORK
- **STATE:** NY
- **ZIP:** 10018

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Auxogyn, Inc.
- **DATE OF NAME CHANGE:** 20150318

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Auxogyn Inc
- **DATE OF NAME CHANGE:** 20120601

?xml version="1.0" ? pgny-20230313

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **March 13, 2023**

**Progyny, Inc.**

(Exact name of Registrant as Specified in Charter)

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-39100** | **27-2220139** |
| (State or Other Jurisdiction <br>of Incorporation) | (Commission <br>File Number) | (IRS Employer <br>Identification No.) |

---

---

| | |
|:---|:---|
| **1359 Broadway <br>New York, New York** | **10018** |
| (Address of Principal Executive Offices) | (Zip Code) |

---

**(212) 888-3124**

(Registrant's Telephone Number, Including Area Code)

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| **Common Stock, $0.0001 par value per share** | **PGNY** | **The Nasdaq Global Select Market** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 7.01 Regulation FD Disclosure.**

On March 13, 2023, Progyny, Inc. (the "Company") disclosed that, even prior to the joint statement by the Federal Reserve, US Treasury Department, and FDIC guaranteeing depositors, less than two percent of the Company's holdings as of December 31, 2022 of cash, cash equivalents, and marketable securities were subject to risk as a result of the FDIC receivership of Silicon Valley Bank ("SVB"). Accordingly, the Company considers its risk exposure relating to SVB to be immaterial.

The information furnished under this Item 7.01, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or subject to the liabilities of that section. The information shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as expressly provided by specific reference in such a filing.

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
| | **Progyny, Inc.** | **Progyny, Inc.** |
| Dated: March 13, 2023 |  |  |
|  | By: | /s/ Peter Anevski |
|  |  | Peter Anevski |
|  |  | Chief Executive Officer |

---